Bioenvision to Present at UBS Global Life Sciences Conference
September 07 2005 - 6:00AM
Business Wire
Bioenvision (NASDAQ:BIVN) announced today that it will participate
in the 2005 UBS Global Life Sciences Conference scheduled for
September 26-29, 2005, in New York City. Dr. Christopher B. Wood,
Chairman & CEO, will represent the Company at this conference.
"We are pleased to be invited to present again at the UBS Global
Life Sciences Conference which has become one of the leading
conferences in the industry" said Dr. Wood. The conference will be
held at the Grand Hyatt New York. Bioenvision's presentation is
scheduled for 9:30 am (EDT) on Wednesday, September 28, 2005. Audio
transmission of the presentation will be available live via the
internet. To access the presentation, please visit
http://www.ibb.ubs.com (click on the "Conferences" icon in the
center right of the page and then follow the link for the Global
Life Sciences Conference). A replay of the presentation will begin
three hours after the actual presentation time and will be
available until October 28, 2005. About Bioenvision Bioenvision's
primary focus is the acquisition, development and distribution of
compounds and technologies for the treatment of cancer. Bioenvision
has a broad pipeline of products for the treatment of cancer,
including: Clofarabine (in co-development with Genzyme
Corporation), Modrenal(R) (for which Bioenvision has obtained
regulatory approval for marketing in the United Kingdom for the
treatment of post-menopausal breast cancer following relapse to
initial hormone therapy), and other products in clinical trials.
Bioenvision is also developing anti-infective technologies,
including the OLIGON technology; an advanced biomaterial that has
been incorporated into various FDA approved medical devices. For
more information on Bioenvision please visit our Web site at
www.bioenvision.com. Certain statements contained herein are
"forward-looking" statements (as such term is defined in the
Private Securities Litigation Reform Act of 1995). Because these
statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Specifically, factors that could cause
actual results to differ materially from those expressed or implied
by such forward-looking statements include, but are not limited to:
risks associated with preclinical and clinical developments in the
biopharmaceutical industry in general and in Bioenvision's
compounds under development in particular; the potential failure of
Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure
to successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for our
compounds under development; acquisitions, divestitures, mergers,
licenses or strategic initiatives that change Bioenvision's
business, structure or projections; the development of competing
products; uncertainties related to Bioenvision's dependence on
third parties and partners; and those risks described in
Bioenvision's filings with the SEC. Bioenvision disclaims any
obligation to update these forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Bioenvision (MM) (NASDAQ): 0 recent articles
More Bioenvision News Articles